Clinical Resources for Clinicians · For clinicians

Anticoagulation in Pregnancy: A Clinical Overview for OB Teams

By the Find Her Doctor editorial team · Updated November 1, 2026 · 6 min read

Low-molecular-weight heparin is the anticoagulant of choice for most pregnant patients. It doesn't cross the placenta, dosing is predictable, and it carries a lower risk of heparin-induced thrombocytopenia and osteoporosis than unfractionated heparin. Warfarin and DOACs are generally avoided, with mechanical heart valves as the main exception, and those patients belong with a specialist team.

Choosing the agent is rarely where things go wrong. In practice, the failure points are the peripartum plan (when to stop, neuraxial timing, when to restart), the postpartum handoff, and the plan that lives only in the prenatal chart and never reaches L&D. This overview is organized around those.

Who ends up on anticoagulation

• Acute VTE in pregnancy or postpartum
• Prior VTE with ongoing or pregnancy-related risk (see thrombophilia testing and VTE prophylaxis)
• High-risk inherited thrombophilia or a strong family history
• Antiphospholipid syndrome, usually with low-dose aspirin
• Mechanical heart valves
• Other: some arrhythmias, cardiomyopathies and Fontan circulations, managed with cardiology

Agents at a glance

The preconception gap. Patients of reproductive age on a DOAC or warfarin should have a pregnancy plan before they need one. When they conceive unexpectedly, switch to LMWH as soon as pregnancy is recognized; warfarin embryopathy risk is concentrated in the first trimester. A practical step: flag every reproductive-age patient on oral anticoagulation in your EHR so the first positive pregnancy test triggers a same-week call, not a routine new-OB slot at 10 weeks.

Dosing intensity

ACOG PB 196 describes prophylactic, intermediate and adjusted-dose (therapeutic) regimens. Exact doses vary by product, weight and indication; use the bulletin, the label and your institutional protocol.

• Prophylactic: fixed low dose, with weight-adjusted options at extremes of weight
• Intermediate: higher fixed or weight-adjusted dosing for some higher-risk scenarios
• Therapeutic (adjusted-dose): weight-based dosing for acute VTE and for patients on long-term anticoagulation

Anti-Xa monitoring

The ASH 2018 pregnancy guideline suggests against routine anti-Xa monitoring to adjust LMWH dose for VTE in most patients. It's reasonable at extremes of body weight and in renal impairment. It's essential for mechanical heart valves, where the ACC/AHA valve guideline calls for dose-adjusted LMWH with anti-Xa monitoring and multidisciplinary care.

Acute VTE in pregnancy

• Start therapeutic LMWH as soon as VTE is suspected and anticoagulation isn't contraindicated. Don't wait for imaging if it will be delayed.
• Continue for the rest of the pregnancy and for at least 6 weeks postpartum, with a total duration of at least 3 months (ACOG, ASH).
• Monitor platelets if the patient was recently exposed to unfractionated heparin, because of HIT risk.

The peripartum plan

This is where coordination earns its keep. Agree on the plan by about 32–34 weeks and document it where L&D, anesthesia and the patient can all find it.

Before delivery

• Planned delivery is common on therapeutic doses. ASH suggests scheduled delivery with prior discontinuation of therapeutic anticoagulation over spontaneous labor in this group.
• Switching to unfractionated heparin at about 36 weeks, or earlier if preterm birth is likely, is a common strategy; the shorter half-life gives more neuraxial flexibility. Some centers continue LMWH and time the last dose instead. Either works if everyone knows which one you chose.
• Patient instructions: hold the next injection at the onset of contractions, rupture of membranes or bleeding, and call L&D. Patients forget this under stress. Put it on a card in their wallet and in their phone.

Neuraxial timing (ASRA / SOAP)

When the interval can't be met, anesthesia will usually recommend general anesthesia for an urgent cesarean. Discuss that contingency with the patient in advance, so it isn't news at 3 a.m. An antenatal anesthesia consult in the third trimester is worth requesting for anyone on therapeutic dosing.

After delivery

• ACOG PB 196 suggests resuming prophylactic anticoagulation 4–6 hours after vaginal delivery or 6–12 hours after cesarean, provided hemostasis is achieved.
• Respect ASRA intervals after neuraxial catheter removal before restarting LMWH.
• For therapeutic indications, some teams start at prophylactic dosing and step up over 24–72 hours depending on bleeding risk.

The postpartum transition

• Continue LMWH for the planned course, usually 6 weeks, or
• Transition to warfarin with LMWH overlap until the INR is therapeutic. This suits patients on long-term anticoagulation who prefer oral therapy, and warfarin is compatible with breastfeeding.
• DOACs are an option only for patients who aren't breastfeeding.

A common failure point: the patient is discharged on day two with a prescription and no clear owner for the INR or the stop date. Name the clinician responsible for the six-week decision before discharge, and make sure the patient knows who it is.

Contraception after VTE

The CDC U.S. Medical Eligibility Criteria rate estrogen-containing methods as unacceptable (category 4) with acute VTE and generally unacceptable with a history of VTE at higher recurrence risk. LNG-IUD, copper IUD, implant and progestin-only methods are generally appropriate. Patients on long-term anticoagulation may have heavier menses, and an LNG-IUD helps. Monitor ferritin.

Bleeding and iron

Anticoagulated patients have higher rates of heavy menstrual bleeding and postpartum blood loss. Check ferritin in pregnancy and postpartum, and treat iron deficiency aggressively, with IV iron when oral iron isn't enough. See postpartum anemia management.

Antiphospholipid syndrome

APS needs a combined plan with maternal-fetal medicine, hematology and often rheumatology. ACOG Practice Bulletin 132 distinguishes patients with a history of thrombosis, who generally receive therapeutic or adjusted-dose anticoagulation in pregnancy, from those with obstetric APS only, for whom prophylactic heparin plus low-dose aspirin is common. Warfarin users with APS should switch to LMWH before or very early in pregnancy, and DOACs aren't appropriate in high-risk APS even outside pregnancy.

Mechanical heart valves

Mechanical valves carry the highest thrombotic risk in pregnancy, and every option trades maternal valve thrombosis against fetal risk. The ACC/AHA valve guideline sets out options including warfarin in selected patients with low dose requirements and dose-adjusted LMWH with anti-Xa monitoring. These patients should be managed by a pregnancy heart team at an experienced center from preconception onward. They aren't candidates for standard VTE protocols.

HIT and heparin allergy

HIT is uncommon with LMWH, especially in obstetric patients, but suspect it when platelets fall substantially 5–10 days after heparin exposure begins or when new thrombosis develops on heparin. Stop all heparin and involve hematology urgently. Injection-site skin reactions are more common and are usually delayed-type hypersensitivity, not HIT. Switching to another LMWH sometimes works, and fondaparinux is a hematology-directed alternative.

A short safety checklist

• Written instructions for every anticoagulated patient: missed doses, bleeding symptoms, what to do when labor starts, who to call.
• The delivery hospital has the plan before 36 weeks, so it isn't first learned at triage. In a region where patients may present to whichever hospital is closest, send it to any likely alternate hospital as well.
• Medication reconciliation at every visit, including over-the-counter NSAIDs and supplements that raise bleeding risk.

Referral partnership in New York

Anticoagulation in pregnancy works best with a named hematology partner involved from the first trimester through the postpartum transition. Premier Hematology & Oncology, which sponsors our professional resources, offers referral pathways and co-management for anticoagulated pregnancies, as well as IV iron infusions for patients with iron deficiency. See our hematology partners page.

Frequently asked questions

Sources

• ACOG — Thromboembolism in Pregnancy (Practice Bulletin No. 196)
• ASH — 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy
• ASRA — Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy (4th edition)
• SOAP — Consensus Statement on the Anesthetic Management of Pregnant and Postpartum Women Receiving Thromboprophylaxis or Higher Dose Anticoagulants (2018)
• ACC/AHA — Guideline for the Management of Patients With Valvular Heart Disease (2020)
• CDC — U.S. Medical Eligibility Criteria for Contraceptive Use (2024)

This article is for general education and is not medical advice. It does not replace an evaluation by a licensed clinician who knows your history. If you think you have a medical emergency, call 911.